A detailed history of Nemes Rush Group LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Nemes Rush Group LLC holds 881 shares of GILD stock, worth $74,523. This represents 0.01% of its overall portfolio holdings.

Number of Shares
881
Previous 6,621 86.69%
Holding current value
$74,523
Previous $485 Million 87.54%
% of portfolio
0.01%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$63.15 - $72.88 $362,481 - $418,331
-5,740 Reduced 86.69%
881 $60.4 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $1.66 Million - $2.03 Million
-23,220 Reduced 77.81%
6,621 $485 Million
Q4 2023

Feb 09, 2024

SELL
$73.27 - $83.09 $16,852 - $19,110
-230 Reduced 0.76%
29,841 $2.42 Billion
Q3 2023

Nov 09, 2023

SELL
$73.94 - $80.67 $21,442 - $23,394
-290 Reduced 0.96%
30,071 $2.25 Billion
Q2 2023

Aug 02, 2023

BUY
$76.01 - $86.7 $2.31 Million - $2.63 Million
30,361 New
30,361 $2.34 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $106B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Nemes Rush Group LLC Portfolio

Follow Nemes Rush Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nemes Rush Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nemes Rush Group LLC with notifications on news.